| Sign In to gain access to subscriptions and/or personal tools. |
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosisDepartment of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland; Department of Neurology, Klinikum rechts der Isar Technische Universität München, München, Germany sellner{at}lrz.tum.de
Department of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland
Department of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland The anti-inflammatory potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, as reflected by modulation of C-reactive protein (CRP), might be beneficial in the treatment of patients with multiple sclerosis (MS). We evaluated serum levels of high-sensitivity (hs)-CRP in relapsing–remitting MS patients receiving interferon-β 1b and atorvastatin as add-on therapy. This study shows that interferon-β treatment is associated with increased serum levels of hs-CRP in MS patients (P < 0.01). In contrast, when atorvastatin is added to interferon-β, hs-CRP serum levels decrease to the normal range (P < 0.05), indicating an anti-inflammatory action of atorvastatin in MS. However, whether add-on treatment with atorvastatin modifies the course of MS remains to be investigated.
Key Words: anti-inflammatory • atorvastatin • C-reactive protein • multiple sclerosis
This version was published on August
1, 2008 Multiple Sclerosis, Vol. 14, No. 7,
981-984 (2008) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
